<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ATACAND HCT - candesartan cilexetil and hydrochlorothiazide tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>ATACAND HCT® 16-12.5<br>(<span class="Italics">candesartan cilexetil−hydrochlorothiazide</span>)<br>TABLETS<br>ATACAND HCT® 32-12.5<br>(<span class="Italics">candesartan cilexetil−hydrochlorothiazide</span>)<br>TABLETS<br>ATACAND HCT® 32–25<br>candesartan cilexetil-hydrochlorothiazide</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-1"></a><p></p>
<h1>USE IN PREGNANCY</h1>
<p class="First"><span class="Bold">When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. </span> When pregnancy is detected, ATACAND HCT should be discontinued as soon as possible.  See <a href="#robinsonja1131737973036">WARNINGS, Fetal/Neonatal Morbidity and Mortality</a>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ATACAND HCT (candesartan cilexetil-hydrochlorothiazide) combines an angiotensin II receptor (type AT<span class="Sub">1</span>) antagonist and a diuretic, hydrochlorothiazide. </p>
<p>Candesartan cilexetil, a nonpeptide, is chemically described as (±)-1-Hydroxyethyl 2-ethoxy-1-[<span class="Italics">p</span>-(<span class="Italics">o</span>-1<span class="Italics">H</span>-tetrazol-5-ylphenyl)benzyl]-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester). </p>
<p></p>
<p>Its empirical formula is C<span class="Sub">33</span>H<span class="Sub">34</span>N<span class="Sub">6</span>O<span class="Sub">6</span>, and its structural formula  is </p>
<p></p>
<div class="Figure"><img alt="Chemical Structure for Candesartan cilexetil" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e50e65d-b79b-46b4-a147-796cb19f1407&amp;name=atacandhct-candeschem1.jpg"></div>
<p>Candesartan cilexetil is a white to off-white powder with a molecular weight of 610.67.   It is practically insoluble in water and sparingly soluble in methanol. Candesartan cilexetil is a racemic mixture containing one chiral center at the cyclohexyloxycarbonyloxy ethyl ester group.  Following oral administration, candesartan cilexetil undergoes hydrolysis at the ester link to form the active drug, candesartan, which is achiral.</p>
<p>Hydrochlorothiazide is 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.  Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span> and its structural formula is</p>
<div class="Figure"><img alt="Chemical Structure for Hydrochlorothiazide" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e50e65d-b79b-46b4-a147-796cb19f1407&amp;name=atacandhct-chemstructure1.jpg"></div>
<p>Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.</p>
<p>ATACAND HCT is available for oral administration in three tablet strengths of candesartan cilexetil and hydrochlorothiazide.</p>
<p>ATACAND HCT 16-12.5 contains 16 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide.  ATACAND HCT 32-12.5 contains 32 mg of candesartan cilexetil and 12.5 mg of hydrochlorothiazide.  ATACAND HCT 32–25 contains 32 mg of candesartan cilexetil and 25 mg of hydrochlorothiazide. The inactive ingredients of the tablets are carboxymethylcellulose calcium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, corn starch, polyethylene glycol 8000, and ferric oxide (yellow).  Ferric oxide (reddish brown) is also added to the 16-12.5 mg and 32–25 mg tablets as colorant.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.  Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland.  Its action is, therefore, independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis.  Candesartan has much greater affinity (&gt;10,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.  Because candesartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin.  Whether this difference has clinical relevance is not yet known.  Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of candesartan on blood pressure.</p>
<p>Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>General</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1.1"></a><p></p>
<h4>Candesartan Cilexetil</h4>
<p class="First">Candesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from the gastrointestinal tract to candesartan, a selective AT<span class="Sub">1 </span>subtype angiotensin II receptor antagonist.   Candesartan is mainly excreted unchanged in urine and feces (via bile).   It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite.   The elimination half-life of candesartan is approximately 9 hours.  After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses up to 32 mg of candesartan cilexetil.   Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing. </p>
<p>Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%.  After tablet ingestion, the peak serum concentration (C<span class="Sub">max</span>) is reached after 3 to 4 hours.  Food with a high fat content does not affect the bioavailability of candesartan after candesartan cilexetil administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. </p>
</div>
</div>
</div>
<div class="Section">
<a name="section-3.3"></a><p></p>
<h2>Metabolism and Excretion</h2>
<div class="Section">
<a name="section-3.3.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg.   When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine.  Following an oral dose of <span class="Sup">14</span>C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces.   Following an intravenous dose of <span class="Sup">14</span>C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces.   Biliary excretion contributes to the elimination of candesartan. </p>
</div>
<div class="Section">
<a name="section-3.3.2"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated unchanged within 24 hours.  </p>
</div>
</div>
<div class="Section">
<a name="section-3.4"></a><p></p>
<h2>Distribution</h2>
<div class="Section">
<a name="section-3.4.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">The volume of distribution of candesartan is 0.13 L/kg.   Candesartan is highly bound to plasma proteins (&gt;99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses.  In rats, it has been demonstrated that candesartan crosses the blood-brain barrier poorly, if at all.  It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus.</p>
</div>
<div class="Section">
<a name="section-3.4.2"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
</div>
</div>
<div class="Section">
<a name="robinsonja1131738329844"></a><a name="section-3.5"></a><p></p>
<h2>Special Populations</h2>
<div class="Section">
<a name="section-3.5.1"></a><p></p>
<h3><span class="Italics">Pediatric</span></h3>
<p class="First">The pharmacokinetics of candesartan cilexetil have not been investigated in patients &lt;18 years of age.</p>
</div>
<div class="Section">
<a name="section-3.5.2"></a><p></p>
<h3><span class="Italics">Geriatric</span></h3>
<p class="First">The pharmacokinetics of candesartan have been studied in the elderly (≥ 65 years).  The plasma concentration of candesartan was higher in the elderly (C<span class="Sub">max</span> was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose.   The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration.   No initial dosage adjustment is necessary. (See <a href="#robinsonja1131738009129">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section">
<a name="section-3.5.3"></a><p></p>
<h3><span class="Italics">Gender</span></h3>
<p class="First">There is no difference in the pharmacokinetics of candesartan between male and female subjects.</p>
</div>
<div class="Section">
<a name="section-3.5.4"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></h3>
<p class="First">In hypertensive patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, serum concentrations of candesartan were elevated.   After repeated dosing, the AUC and C<span class="Sub">max</span>were approximately doubled in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min/1.73m<span class="Sup">2</span>) compared to patients with normal kidney function. The pharmacokinetics of candesartan in hypertensive patients undergoing hemodialysis are similar to those in hypertensive patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.   Candesartan cannot be removed by hemodialysis.   No initial dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.  </p>
<p>Thiazide diuretics are eliminated by the kidney, with a terminal half-life of 5-15 hours.  In a study of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean creatinine clearance of 19 mL/min), the half-life of hydrochlorothiazide elimination was lengthened to 21 hours. (See <a href="#robinsonja1131738009129">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section">
<a name="robinsonja1131738514576"></a><a name="section-3.5.5"></a><p></p>
<h3><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></h3>
<p class="First">The pharmacokinetics of candesartan were compared in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to matched healthy volunteers following a single dose of 16 mg candesartan cilexetil. The AUC for candesartan in patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was increased 30% and 145% respectively.  The C<span class="Sub">max</span> for candesartan was increased 56% and 73% respectively.  The pharmacokinetics of candesartan in severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied.  No dose adjustment is recommended for patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, consideration should be given to initiation of ATACAND at a lower dose, such as 8 mg.  If a lower starting dose is selected for candesartan cilexetil, ATACAND HCT is not recommended for initial titration because the appropriate initial starting dose of candesartan cilexetil cannot be given. (See <span class="Bold"><a href="#robinsonja1131738009129">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Thiazide diuretics should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (See <a href="#robinsonja1131738009129">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
</div>
<div class="Section">
<a name="section-3.6"></a><p></p>
<h2>Pharmacodynamics</h2>
<div class="Section">
<a name="section-3.6.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner.   After 1 week of once-daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours.</p>
<p>Plasma concentrations of angiotensin I and angiotensin II, and plasma renin activity (PRA), increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to healthy subjects and hypertensive patients.  ACE activity was not altered in healthy subjects after repeated candesartan cilexetil administration.  The once-daily administration of up to 16 mg of candesartan cilexetil to healthy subjects did not influence plasma aldosterone concentrations, but a decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients. In spite of the effect of candesartan cilexetil on aldosterone secretion, very little effect on serum potassium was observed.</p>
<p>In multiple-dose studies with hypertensive patients, there were no clinically significant changes in metabolic function including serum levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, glucose, or uric acid.   In a 12-week study of 161 patients with non-insulin-dependent (type 2) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, there was no change in the level of HbA<span class="Sub">1c</span>.</p>
</div>
<div class="Section">
<a name="section-3.6.2"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
</div>
</div>
<div class="Section">
<a name="section-3.7"></a><p></p>
<h2>Clinical Trials</h2>
<div class="Section">
<a name="section-3.7.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil−Hydrochlorothiazide</span></h3>
<p class="First">Of 12 controlled clinical trials involving 4588 patients, 5 were double-blind, placebo controlled and evaluated the antihypertensive effects of single entities vs the combination.  These 5 trials, of 8 to 12 weeks duration, randomized 3037 hypertensive patients.  Doses ranged from 2 to 32 mg candesartan cilexetil and from 6.25 to 25 mg hydrochlorothiazide administered once daily in various combinations.</p>
<p>The combination of candesartan cilexetil-hydrochlorothiazide resulted in placebo-adjusted decreases in sitting systolic and diastolic blood pressures of 14-18/8-11 mm Hg at doses of 16-12.5 mg and 32-12.5 mg.  The combination of candesartan cilexetil and hydrochlorothiazide 32-25 mg resulted in placebo-adjusted decreases in sitting systolic and diastolic blood pressures of 16-19/9-11 mm Hg.  The placebo corrected trough to peak ratio was evaluated in a study of candesartan cilexetil-hydrochlorothiazide 32-12.5 mg and was 88%.</p>
<p>Most of the antihypertensive effect of the combination of candesartan cilexetil and hydrochlorothiazide was seen in 1 to 2 weeks with the full effect observed within 4 weeks.  In long-term studies of up to 1 year, the blood pressure lowering effect of the combination was maintained.  The antihypertensive effect was similar regardless of age or gender, and overall response to the combination was similar in black and non-black patients.  No appreciable changes in heart rate were observed with combination therapy in controlled trials.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First">ATACAND HCT is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.   This fixed dose combination is not indicated for initial therapy (see <a href="#robinsonja1131738009129">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">ATACAND HCT is contraindicated in patients who are hypersensitive to any component of this product. </p>
<p>Because of the hydrochlorothiazide component, this product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="robinsonja1131738429592"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<div class="Section">
<a name="robinsonja1131737973036"></a><a name="section-6.1"></a><p></p>
<h2>Fetal/Neonatal Morbidity and Mortality</h2>
<p class="First">Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered to pregnant women.  Several dozen cases have been reported in the world literature in patients who were taking angiotensin- converting enzyme inhibitors.  Post-marketing experience has identified reports of fetal and neonatal toxicity in babies born to women treated with candesartan cilexetil during pregnancy.  Because candesartan cilexetil is a component of ATACAND HCT, when pregnancy is detected, ATACAND HCT should be discontinued as soon as possible.</p>
<p>The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> has also been reported, presumably resulting from decreased fetal renal function; <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> in this setting has been associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development.  <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.</p>
<p>These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester.  Mothers whose embryos and fetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed.  Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of ATACAND HCT as soon as possible.</p>
<p>Rarely (probably less often than once in every thousand pregnancies), no alternative to a drug acting on the renin-angiotensin system will be found.  In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intra-amniotic environment.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, ATACAND HCT should be discontinued unless it is considered life saving for the mother.  Contraction stress testing (CST), a nonstress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy.  Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of <span class="Italics">in utero</span> exposure to an angiotensin II receptor antagonist should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.  If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, attention should be directed toward support of blood pressure and renal perfusion.  Exchange transfusion or dialysis may be required as means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
<div class="Section">
<a name="section-6.1.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil-Hydrochlorothiazide</span></h3>
<p class="First">There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other adverse effects on embryo-fetal development when pregnant mice, rats or rabbits were treated orally with candesartan cilexetil alone or in combination with hydrochlorothiazide.  For mice, the maximum dose of candesartan cilexetil was 1000 mg/kg/day (about 150 times the maximum recommended daily human dose [MRHD]<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>). For rats, the maximum dose of candesartan cilexetil was 100 mg/kg/day (about 31 times the MRHD<a href="#footnote-1" class="Sup">1</a>).  For rabbits, the maximum dose of candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD<a href="#footnote-1" class="Sup">1</a>).  In each of these studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15 times the MRHD<a href="#footnote-1" class="Sup">1</a> in mouse, rats, and rabbit, respectively).  There was no evidence of harm to the rat or mouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant rat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.</p>
<p></p>
<p>Thiazides cross the placental barrier and appear in cord blood.  There is a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Doses compared on the basis of body surface area.  MRHD considered to be 32 mg for candesartan cilexetil and 12.5 mg for hydrochlorothiazide.</dd>
</dl>
</div>
</div>
<div class="Section">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- and Salt-Depleted Patients</h2>
<p class="First">Based on adverse events reported from all clinical trials of ATACAND HCT, excessive reduction of blood pressure was rarely seen in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with candesartan cilexetil and hydrochlorothiazide (0.4%).  Initiation of antihypertensive therapy may cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in patients with intravascular volume- or sodium- depletion, eg, in patients treated vigorously with diuretics or in patients on dialysis.  These conditions should be corrected prior to administration of ATACAND HCT, or the treatment should start under close medical supervision (see <a href="#robinsonja1131738009129">DOSAGE AND ADMINISTRATION</a>).</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patients should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline.  A transient hypotensive response is not a contraindication to further treatment which usually can be continued without difficulty once the blood pressure has stabilized.</p>
<p></p>
<div class="Section">
<a name="section-6.2.1"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1.1"></a><p></p>
<h4>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h4>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation.  Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.  The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.  Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.  Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
<div class="Section">
<a name="section-6.2.1.2"></a><p></p>
<h4>Impaired Hepatic Function</h4>
<p class="First">Thiazide diuretics should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
</div>
<div class="Section">
<a name="section-6.2.1.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section">
<a name="section-6.2.1.4"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></h4>
<p class="First">Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section">
<a name="section-6.2.1.5"></a><p></p>
<h4>Lithium Interaction </h4>
<p class="First">Lithium generally should not be given with thiazides (see <a href="#robinsonja1131738289985">PRECAUTIONS, Drug Interactions, Hydrochlorothiazide, Lithium</a>).</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section">
<a name="section-7.1.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil−Hydrochlorothiazide</span></h3>
<p class="First">In clinical trials of various doses of candesartan cilexetil and hydrochlorothiazide, the incidence of hypertensive patients who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 mEq/L) was 2.5% versus 2.1% for placebo; the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.7 mEq/L) was 0.4% versus 1.0% for placebo.  No patient receiving ATACAND HCT 16-12.5 mg or 32-12.5 mg was discontinued due to increases or decreases in serum potassium.  Overall, the combination of candesartan cilexetil and hydrochlorothiazide had no clinically significant effect on serum potassium.</p>
<p><span class="Italics">Candesartan </span></p>
<p><span class="Italics">Major Surgery/Anesthesia</span>— <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may occur during major surgery and anesthesia in patients treated with angiotensin II receptor antagonists, including candesartan, due to blockade of the renin-angiotensin system. Very rarely, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p>
</div>
<div class="Section">
<a name="section-7.1.2"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: namely, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids.  Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, or after prolonged therapy.  Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (eg, increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p>Although any chloride deficit is generally mild and usually does not require specific treatment, except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening.  In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p>In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required.  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur with thiazide diuretics.  Thus <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during thiazide therapy.</p>
<p>The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident consider withholding or discontinuing diuretic therapy.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
<p>Thiazides may decrease urinary calcium excretion.  Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.  Marked <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be evidence of hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>.  Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with thiazide diuretic therapy.</p>
</div>
</div>
<div class="Section">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<div class="Section">
<a name="section-7.2.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with candesartan cilexetil.  In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (eg, patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Similar results may be anticipated in patients treated with candesartan cilexetil. (See <a href="#robinsonja1131738329844">CLINICAL PHARMACOLOGY, Special Populations</a>.)</p>
<p>In studies of ACE inhibitors in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen (BUN) have been reported.  There has been no long-term use of candesartan cilexetil in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but similar results may be expected.</p>
</div>
<div class="Section">
<a name="section-7.2.2"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">Thiazides should be used with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.  In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>.  Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
</div>
<div class="Section">
<a name="section-7.3"></a><p></p>
<h2>Impaired Hepatic Function</h2>
<div class="Section">
<a name="section-7.3.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">Based on pharmacokinetic data significant increases in candesartan AUC and C<span class="Sub">max</span> in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have been demonstrated.  (See <a href="#robinsonja1131738329844">CLINICAL PHARMACOLOGY, Special Populations</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<div class="Section">
<a name="section-7.4.1"></a><p></p>
<h3><span class="Italics">Pregnancy</span></h3>
<p class="First">Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to drugs that act on the renin-angiotensin system, and they should also be told that these consequences do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester.  These patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
<div class="Section">
<a name="section-7.4.2"></a><p></p>
<h3><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></h3>
<p class="First">A patient receiving ATACAND HCT should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician.  The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, ATACAND HCT should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section">
<a name="section-7.4.3"></a><p></p>
<h3><span class="Italics">Potassium Supplements</span></h3>
<p class="First">A patient receiving ATACAND HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.5"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section">
<a name="section-7.5.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers.  Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.</p>
<p>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  These effects are usually reversible.  Monitor renal function periodically in patients receiving candesartan and NSAID therapy.</p>
<p>  The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
</div>
<div class="Section">
<a name="robinsonja1131738289985"></a><a name="section-7.5.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Lithium</span> − Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.  An increase in serum lithium concentration has been reported during concomitant administration of lithium with candesartan cilexetil, so careful monitoring of serum lithium levels is recommended during concomitant use.</p>
</div>
<div class="Section">
<a name="section-7.5.3"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">When administered concurrently the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics</span> − Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Antidiabetic drugs (oral agents and insulin)</span> − Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Other antihypertensive drugs</span> − Additive effect or potentiation.</p>
<p><span class="Italics">Cholestyramine and colestipol resins</span> − Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.  Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.</p>
<p><span class="Italics">Corticosteroids, ACTH</span> − Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Pressor amines (eg, norepinephrine)</span> − Possible decreased response to pressor amines but not sufficient to preclude their use.</p>
<p><span class="Italics">Skeletal muscle relaxants, nondepolarizing (eg, tubocurarine)</span> −Possible increased responsiveness to the muscle relaxant.</p>
<p><span class="Italics">Lithium</span> −Generally should not be given with diuretics.  Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.  Refer to the package insert for lithium preparations before use of such preparations with ATACAND HCT.</p>
<p><span class="Italics">Non-steroidal Anti-inflammatory Drugs</span> − In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.  Therefore, when ATACAND HCT and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been conducted with the combination of candesartan cilexetil and hydrochlorothiazide.  There was no evidence of carcinogenicity when candesartan cilexetil was orally administered to mice and rats for up to 104 weeks at doses up to 100 and 1000 mg/kg/day, respectively.  Rats received the drug by gavage whereas mice received the drug by dietary administration.  These (maximally-tolerated) doses of candesartan cilexetil provided systemic exposures to candesartan (AUCs) that were, in mice, approximately 7 times and, in rats, more than 70 times the exposure in man at the maximum recommended daily human dose (32 mg).  Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day).  The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Candesartan cilexetil or candesartan (the active metabolite), in combination with hydrochlorothiazide, tested positive <span class="Italics">in vitro</span> in the Chinese hamster lung (CHL) chromosomal aberration assay and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagenicity assay.  The candesartan cilexetil/hydrochlorothiazide combination tested negative for mutagenicity in bacteria (Ames test), for unscheduled DNA synthesis in rat liver, for chromosomal aberrations in rat bone marrow and for micronuclei in mouse bone marrow.</p>
<p>Both candesartan and its O-deethyl metabolite tested positive for genotoxicity in the <span class="Italics">in vitro</span> CHL chromosomal aberration assay.  Neither compound tested positive in the Ames microbial mutagenesis assay or in the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay.  Candesartan (but not its O-deethyl metabolite) was also evaluated <span class="Italics">in vivo</span> in the mouse micronucleus test and <span class="Italics">in vitro</span> in the Chinese hamster ovary (CHO) gene mutation assay, in both cases with negative results.  Candesartan cilexetil was evaluated in the Ames test, the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay, the <span class="Italics">in vivo</span> rat hepatocyte unscheduled DNA synthesis assay and the <span class="Italics">in vivo</span> mouse micronucleus test, in each case with negative results.  Candesartan cilexetil was not evaluated in the CHL chromosomal aberration or CHO gene mutation assays.</p>
<p>When hydrochlorothiazide was tested alone, positive results were obtained <span class="Italics">in vitro</span> in the CHO sister chromatid exchange (clastogenicity) and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (mutagenicity) assays and in the <span class="Italics">Aspergillus nidulans</span> non-disjunciton assay.  Hydrochorothiazide was not genotoxic <span class="Italics">in vitro</span> in the Ames test for point mutations and the CHO test for chromosomal aberrations, or <span class="Italics">in vivo</span> in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene.</p>
<p>No fertility studies have been conducted with the combination of candesartan cilexetil and hydrochlorothiazide. Fertility and reproductive performance were not affected in studies with male and female rats given oral doses of up to 300 mg candesartan cilexetil/kg/day (83 times the maximum daily human dose of 32 mg on a body surface area basis).  Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.</p>
</div>
<div class="Section">
<a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Categories C</span> (first trimester) <span class="Italics">and D</span> (second and third trimesters). See <a href="#robinsonja1131737973036">WARNINGS, Fetal/Neonatal Morbidity and Mortality</a>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether candesartan is excreted in human milk, but candesartan has been shown to be present in rat milk.  Thiazides appear in human milk.  Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the total number of subjects in all clinical studies of ATACAND HCT (2831), 611 (22%) were 65 and over, while 94 (3%) were 75 and over.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Hydrochlorothiazide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<div class="Section">
<a name="section-8.1"></a><p></p>
<h2><span class="Italics">Candesartan Cilexetil-Hydrochlorothiazide</span></h2>
<p class="First">ATACAND HCT has been evaluated for safety in more than 2800 patients treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  More than 750 of these patients were studied for at least six months and more than 500 patients were treated for at least one year.  Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse events reported with ATACAND HCT was comparable to placebo.  The overall frequency of adverse experiences was not related to dose, age, gender, or race.</p>
<p>In placebo-controlled trials that included 1089 patients treated with various combinations of candesartan cilexetil (doses of 2-32 mg) and hydrochlorothiazide (doses of 6.25-25 mg) and 592 patients treated with placebo, adverse events, whether or not attributed to treatment, occurring in greater than 2% of patients treated with ATACAND HCT and that were more frequent for ATACAND HCT than placebo were: <span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorder</span>:</span> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (3.6% vs 3.0%); <span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (3.3% vs 2.4%); <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms (2.5% vs 1.9%); <span class="Bold Italics">Central/Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.9% vs 1.2%).  </p>
<p>The frequency of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> was greater than 2% (2.9%) in patients treated with ATACAND HCT but was less frequent than the rate in patients treated with placebo (5.2%).</p>
<p></p>
<p>Other adverse events that have been reported, whether or not attributed to treatment, with an incidence of 0.5% or greater from the more than 2800 patients worldwide treated with ATACAND HCT included:<span class="Bold"></span><span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">inflicted injury</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>; <span class="Bold Italics">Central and Peripheral Nervous System</span><span class="Italics">:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>; <span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>; <span class="Bold Italics">Musculoskeletal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="372409" conceptname="Sciatica">sciatica</span>; <span class="Bold Italics">Gastrointestinal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="Bold Italics">Metabolic and Nutritional Disorders:</span><span class="Bold"></span> <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>,  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, increased BUN, creatine phosphokinase increased; <span class="Bold Italics">Urinary System Disorders:</span>  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>; <span class="Bold Italics">Liver/Biliary System Disorders:</span> <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, increased transaminase levels; <span class="Bold Italics">Heart Rate and Rhythm Disorders:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="Bold Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>; <span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">ECG abnormal</span>; <span class="Bold Italics">Skin and Appendages Disorders:</span>  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="Bold Italics">Platelet/<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>-<span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span>:</span><span class="Italics"></span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; <span class="Bold Italics">Resistance Mechanism Disorders:</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>;  <span class="Bold Italics">Vision Disorders:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>; <span class="Bold Italics">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. </p>
<p>Reported events seen less frequently than 0.5% included <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. </p>
<div class="Section">
<a name="section-8.1.1"></a><p></p>
<h3><span class="Italics">Candesartan Cilexetil</span></h3>
<p class="First">Other adverse experiences that have been reported with candesartan cilexetil, without regard to causality,  were: <span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="Bold Italics">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>; <span class="Bold Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>; <span class="Bold Italics">Urinary System Disorders:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>.</p>
</div>
</div>
<div class="Section">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">Post-Marketing Experience</span></h2>
<p class="First">The following have been very rarely reported in post-marketing experience with candesartan cilexetil:</p>
<p><span class="Bold">Digestive:</span> Abnormal hepatic function and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.  </p>
<p><span class="Bold">Hematologic:</span>  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p><span class="Bold">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold">Renal: </span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p><span class="Bold">Skin and Appendages Disorders:</span>  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers.</p>
<div class="Section">
<a name="section-8.2.1"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">Other adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold Italics">Body As A Whole:</span>  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="Bold Italics">Cardiovascular:</span>  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs); <span class="Bold Italics">Digestive:</span>  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>;  <span class="Bold Italics">Hematologic:</span>  <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>;  <span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span>  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>),  <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>;  <span class="Bold Italics">Metabolic:</span>  <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>;  <span class="Bold Italics">Musculoskeletal:</span><span class="Bold"></span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>;  <span class="Bold Italics">Nervous System/Psychiatric:</span><span class="Italics"></span> <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>;  <span class="Bold Italics">Renal:</span>  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>;  <span class="Bold Italics">Skin:</span>  <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>;  <span class="Bold Italics">Special Senses:</span>  transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>; <span class="Bold Italics">Urogenital:</span><span class="Bold"></span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
</div>
</div>
<div class="Section">
<a name="section-8.3"></a><p></p>
<h2>Laboratory Test Findings</h2>
<p class="First">In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with the administration of ATACAND HCT. </p>
<p><span class="Italics">Creatinine, Blood Urea Nitrogen</span>— Minor increases in blood urea nitrogen (BUN) and serum creatinine were observed infrequently.  One patient was discontinued from ATACAND HCT due to increased BUN.  No patient was discontinued due to an increase in serum creatinine.</p>
<p><span class="Italics">Hemoglobin and Hematocrit</span>—Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL  and 0.4 volume percent, respectively) were observed in patients treated with ATACAND HCT, but were rarely of clinical importance.  </p>
<p><span class="Italics">Potassium</span>— A small decrease (mean decrease of 0.1 mEq/L) was observed in patients treated with ATACAND HCT.  In placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> was reported in 0.4% of patients treated with ATACAND HCT as compared to 1.0% of patients treated with hydrochlorothiazide or 0.2% of patients treated with placebo. </p>
<p><span class="Italics">Liver Function Tests</span>—Occasional elevations of liver enzymes and/or serum bilirubin have occurred.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section">
<a name="section-9.1"></a><p></p>
<h2><span class="Italics">Candesartan Cilexetil−Hydrochlorothiazide</span></h2>
<p class="First">No lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide.  In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg.</p>
<p>Limited data are available in regard to overdosage with candesartan cilexetil in humans.  The most likely manifestations of overdosage with candesartan cilexetil would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation.  If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be initiated.  For hydrochlorothiazide, the most common signs and symptoms observed are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.  If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>Candesartan cannot be removed by hemodialysis.  The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.</p>
<div class="Section">
<a name="section-9.1.1"></a><p></p>
<h3><span class="Italics">Treatment</span></h3>
<p class="First">To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consult your Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians’ Desk Reference (PDR)</span>. In managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consider the possibilities of multiple-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, drug-drug interactions, and altered pharmacokinetics in your patient.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="robinsonja1131738009129"></a><a name="section-10"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First">The usual recommended starting dose of candesartan cilexetil is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. ATACAND can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg.  Patients requiring further reduction in blood pressure should be titrated to 32 mg.  Doses larger than 32 mg do not appear to have a greater blood pressure lowering effect. </p>
<p>Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily.</p>
<p>To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. </p>
<p>The side effects (See <a href="#robinsonja1131738429592">WARNINGS</a>) of candesartan cilexetil are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) and dose-independent phenomena (eg, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>), the former much more common than the latter.</p>
<p>Therapy with any combination of candesartan cilexetil and hydrochlorothiazide will be associated with both sets of dose-independent side effects. </p>
<p><span class="Bold">Replacement Therapy:</span> The combination may be substituted for the titrated components. </p>
<p><span class="Bold">Dose Titration by Clinical Effect:</span> A patient whose blood pressure is not controlled on 25 mg of hydrochlorothiazide once daily can expect an incremental effect from ATACAND HCT 16-12.5 mg.  A patient whose blood pressure is controlled on 25 mg of hydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or incremental blood pressure effects from ATACAND HCT 16-12.5 mg and serum potassium may improve.</p>
<p>A patient whose blood pressure is not controlled on 32 mg of ATACAND can expect incremental blood pressure effects from ATACAND HCT 32-12.5 mg and then 32-25 mg.  The maximal antihypertensive effect of any dose of ATACAND HCT can be expected within 4 weeks of initiating that dose.</p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span> The usual regimens of therapy with ATACAND HCT may be followed as long as the patient’s creatinine clearance is &gt; 30 mL/min.  In patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, loop diuretics are preferred to thiazides, so ATACAND HCT is not recommended. </p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span>The usual regimens of therapy with ATACAND HCT may be followed in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  In patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, consideration should be given to initiation of ATACAND at a lower dose, such as 8 mg.  If a lower starting dose is selected for candesartan cilexetil, ATACAND HCT is not recommended for initial titration because the appropriate initial starting dose of candesartan cilexetil cannot be given. (See <span class="Bold"><a href="#robinsonja1131738514576">CLINICAL PHARMACOLOGY, Special Populations, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></span>).</p>
<p>Thiazide diuretics should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; therefore, care should be exercised with dosing of ATACAND HCT.  </p>
<p>ATACAND HCT may be administered with other antihypertensive agents. </p>
<p>ATACAND HCT may be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">No. 3825 — Tablets ATACAND HCT 16-12.5, are peach, oval, biconvex, non-film-coated tablets, scored on both sides and coded with ACS on one side.  They are supplied as follows: </p>
<a name="i0d4e8066-8b9d-4bdf-8226-ec7975a5d78e"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-4729-0<br>
</td>
</tr></tbody></table>
<p>No. 3826 — Tablets ATACAND HCT 32-12.5, are yellow, oval, biconvex,  non-film-coated tablets, scored on both sides and coded with ACJ on one side.  They are supplied as follows: </p>
<a name="id9afdef6-4464-4173-8201-9a0ada87ba17"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-4869-0<br>
</td>
</tr></tbody></table>
<p></p>
<br><div class="Section">
<a name="section-11.1"></a><p></p>
<h2>Storage:</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].  Keep container tightly closed.</p>
<p>ATACAND HCT is a trademark of the AstraZeneca group of companies </p>
<p>©AstraZeneca 2008</p>
<p>Manufactured under the license from Takeda Pharmaceutical Company, Ltd.</p>
<p>by: AstraZeneca AB, S-151 85 Södertälje, Sweden</p>
<p>for:  AstraZeneca LP, Wilmington, DE 19850</p>
<p>Made in Sweden</p>
<p></p>
<p>Rev. 04/11</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma     74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PACKAGE LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Atacand HCT16/12.5mg " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e50e65d-b79b-46b4-a147-796cb19f1407&amp;name=4729.jpg"></div>
<br><div class="Figure"><img alt="Atacand HCT 32/12.5mg " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e50e65d-b79b-46b4-a147-796cb19f1407&amp;name=4869.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATACAND HCT 		
					</strong><br><span class="contentTableReg">candesartan cilexetil and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4729(NDC:0186-0162)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CANDESARTAN CILEXETIL</strong> (CANDESARTAN) </td>
<td class="formItem">CANDESARTAN CILEXETIL</td>
<td class="formItem">16 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACS;162</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4729-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021093</td>
<td class="formItem">01/21/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATACAND HCT 		
					</strong><br><span class="contentTableReg">candesartan cilexetil and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4869(NDC:0186-0322)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CANDESARTAN CILEXETIL</strong> (CANDESARTAN) </td>
<td class="formItem">CANDESARTAN CILEXETIL</td>
<td class="formItem">32 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACJ;322</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4869-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021093</td>
<td class="formItem">11/13/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>714d8082-a99d-4580-9ff6-2c569bbbda65</div>
<div>Set id: 8e50e65d-b79b-46b4-a147-796cb19f1407</div>
<div>Version: 2</div>
<div>Effective Time: 20120202</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
